Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference
About
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.
For more information, please visit www.soleno.life.
CONTACT:
LifeSci Advisors, LLC
212-915-2578
Source: Soleno Therapeutics